Nitorum Capital, L.P. Grifols Sa Transaction History

Nitorum Capital, L.P.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$10.6 - $13.28 $12.2 Million - $15.2 Million	-1,148,117 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$10.37 - $12.73 $23 Million - $28.2 Million	-2,217,147 Reduced 65.88%	1,148,117 $13.4 Million
Q4 2021 Feb 14, 2022	SELL	$10.21 - $15.27 $454,988 - $680,477	-44,563 Reduced 1.31%	3,365,264 $37.8 Million
Q2 2021 Aug 16, 2021	SELL	$16.62 - $18.94 $281,825 - $321,165	-16,957 Reduced 0.49%	3,409,827 $59.2 Million
Q4 2020 Feb 16, 2021	BUY	$16.86 - $19.67 $251,214 - $293,083	14,900 Added 0.44%	3,426,784 $63.2 Million
Q2 2020 Aug 14, 2020	BUY	$18.24 - $21.45 $13.7 Million - $16.1 Million	751,100 Added 28.23%	3,411,884 $62.2 Million
Q1 2020 May 15, 2020	BUY	$16.28 - $25.63 $43.3 Million - $68.2 Million	2,660,784 New	2,660,784 $53.6 Million

164

140M

288K

389K

Ticker GRFS
Exchange OTC
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 678,910,976
Market Cap $5.31B
Description
Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solut...

Get notified when there are updates to the investment portfolio of Nitorum Capital, L.P., based on Form 13F filings with the SEC.

Stay updated on Nitorum Capital, L.P. with notifications on news.